This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Cantor Fitzgerald Maintains Overweight on Ameresco, Lowers Price Target to $36

Cantor Fitzgerald analyst Manish A. Somaiya maintains Ameresco (NYSE:AMRC) with a Overweight and lowers the price target from $44 to $36.

Ameresco shares are trading lower. The company announced the departure of its CFO, Mark Chiplock.

8-K filing — Ameresco, Inc. (AMRC)

Filed: 2026-08-19 AccNo: 0001628280-26-057986 Size: 145 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Ameresco Reiterates Its Guidance For FY26 Revenue Of $2B-$2.2B, Adjusted EBITDA Of $250M-$270M, And Non-GAAP EPS Of $1.15-$1.35

Ameresco is pleased to reiterate its guidance for full year 2026 revenue of $2.0 billion to $2.2 billion, Adjusted EBITDA of $250 million to $270 million, and Non-GAAP EPS of $1.15 to $1.35.

Barclays Maintains Overweight on Kanzhun, Raises Price Target to $20

Barclays analyst Jiong Shao maintains Kanzhun (NASDAQ:BZ) with a Overweight and raises the price target from $19 to $20.

Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday

U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings and raising forecasts. Other top gainers include Kanzhun, Capricor Therapeutics, Semtech Corp, and more.